R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)

The goal of this clinical trial is to learn if R-3750 is safe in \[in patients with late-stage, non-resolving Acute Respiratory Distress Syndrome (ARDS) . The main question\[s\] it aims to answer are: 1. the favorable safety profile 2. clinical improvement that includes reduced ventilator dependence and improved lung function. Participants will be given oral capsules daily and/or enteral nasogastric or orogastric (NG/OG tube) if necessary.

NCT Number	NCT07646028
Lead Sponsor	Rise Therapeutics LLC
Conditions	Acute Respiratory Distress Syndrome
Enrollment	20 participants
Start Date	2026-09-01
Primary Completion	2028-10-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-12